Correlation Engine 2.0
Clear Search sequence regions


  • acceptor (1)
  • amino acid (1)
  • b cell lymphoma (7)
  • b cells (3)
  • c Myc (9)
  • c- b (3)
  • cancer (1)
  • cell death (1)
  • dna breaks (1)
  • dna damage (3)
  • gene (2)
  • help (1)
  • mice (2)
  • mice knockout (1)
  • Myc (2)
  • Myc protein (1)
  • PARP (3)
  • PARP 1 (7)
  • PARP 2 (8)
  • strand breaks (1)
  • t cells (1)
  • Sizes of these terms reflect their relevance to your search.

    Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc-driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the Eμ-Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic Eμ-Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc-driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc-driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc-driven tumors. © 2022 by The American Society of Hematology.

    Citation

    Miguel A Galindo-Campos, Nura Lutfi, Sarah Bonnin, Carlos Martínez, Talia Velasco-Hernandez, Violeta García-Hernández, Juan Martín-Caballero, Coral Ampurdanés, Ramón Gimeno, Lluis Colomo, Gaël Roué, Guillaume Guilbaud, Françoise Dantzer, Pilar Navarro, Matilde Murga, Oscar Fernández-Capetillo, Anna Bigas, Pablo Menéndez, Julian E Sale, José Yélamos. Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice. Blood. 2022 Jan 13;139(2):228-239

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 34359075

    View Full Text